Telix Pharmaceuticals announces first patient dosed in Phase II CA-NINE trial

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Oct 03 2024

0mins

Trial Announcement: Telix Pharmaceuticals has initiated a Phase II trial, named 'CA-NINE', to evaluate the effectiveness of its investigational PET agent TLX250-CDx in detecting recurrent clear cell renal cell carcinoma (ccRCC) after surgery.
Study Details: The trial, led by Professor Brian Shuch at UCLA, will involve 91 patients and aims to compare TLX250-CDx PET/CT imaging with conventional methods to identify recurrence and metastatic disease in ccRCC patients.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.